QUANTITATIS (ANCIEN) SARL

About QUANTITATIS (ANCIEN) SARL

QUANTITATIS (ANCIEN) SARL appears in the market documentation of Plant Advanced Technologies PAT as a legal entity linked to Jean-Paul Fèvre and referenced in insider-transaction and governance disclosures. Publicly available sources do not provide a conventional personal biography; instead, they consistently identify the entity in a corporate and regulatory context, where it is described as “PDG” within the company’s market filings and insider-trading records. This indicates an active role connected to leadership, ownership, or representation around PAT rather than a standalone executive profile with extensive public-facing history. Within Plant Advanced Technologies PAT, the entity is associated with a French biotechnology company focused on the identification, optimization, and production of rare plant-based biomolecules for pharmaceutical laboratories, cosmetics groups, and green chemistry applications. PAT presents itself as a company driven by innovation, the development of plant-derived high-value ingredients, and the regular launch of new active compounds. In that setting, QUANTITATIS (ANCIEN) SARL is part of the ownership and governance ecosystem of a niche listed company on Euronext Growth Paris. The most concrete public evidence concerns recent stock-market transactions and AMF disclosures, including purchases and sales filed under the entity’s name. These filings show that QUANTITATIS (ANCIEN) SARL has been actively involved in capital movements and regulatory reporting, underscoring an operational role in shareholder monitoring, transparency obligations, and listed-company governance. Overall, the public profile of QUANTITATIS (ANCIEN) SARL is best understood as that of a governance- and ownership-linked corporate vehicle tied to Jean-Paul Fèvre and Plant Advanced Technologies PAT. Its significance lies in its proximity to strategic control, market disclosures, and the capital structure of an innovation-led industrial company. In SEO terms, it is a relevant name for corporate governance, insider activity, and leadership around a French listed biotech group.